Karoline Rosenkranz

[ERA - European Renal Association @ERAkidney]

🎉Congratulations to Karoline Rosenkranz who received the 2023 ERA National Grant during the German Society of Nephrology Congress.
🏆National Societies can award young nephrologists who submit an Abstract with an ERA National Grant.
📬Ask your National Society for more info!

[JASN_News @JASN_News]

Inhibitors of the renin-angiotensin system (RAS), SGLT-2, and the mineralocorticoid receptor (MR) were superior to dual RAS/SGLT2 blockade in attenuating CKD progression in a mouse model of Alport syndrome https://t.co/Tn5IHSKP2g

@hjanders_hans @RosKaroAT @cirluigi @LaBOORatory

[Hans-Joachim Anders @hjanders_hans]

Now in @JASN_News. Finerenone Added to RAS/SGLT2 Blockade for Chronic Kidney Disease in Alport Syndrome. Results of a Randomized Contr… https://t.co/Y5spN8YVFs

[Karoline Rosenkranz @RosKaroAT]

@immunolrosgraz Danke!!😊

[Karoline Rosenkranz @RosKaroAT]

@hjanders_hans @LMU_Uniklinikum @LMU_Muenchen @dgimev @hjanders_hans @LMU_Uniklinikum a big thank you for the possibility, for all the support I received during this project and for being my mentor! It was a very interesting and positively educative year!😄

[Hans-Joachim Anders @hjanders_hans]

⁦⁦@LMU_Uniklinikum⁩ ⁦@LMU_Muenchen⁩ med. student Karoline Rosenkranz awarded today by the German Society of Internal Medicine ⁦@dgimev⁩ with the 🥇young investigator award for her experimental work on #empagliflozin and #finerenone in #CKD of #Alport syndrome